BSECompany Update24 Aug 2026 · 24 Aug 2026, 08:24 pm
Intimation of Investor Meet
Natco Pharma Ltd · 524816
✦ AI SummaryMgmt Change
Natco Pharma Ltd has announced an investor meet, where company officials will participate in discussions with investors. The meet will be held on various dates in August 2026, and the company's latest investor presentation is available on its website.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment6/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Attachments (1)
📄pdf
Download →
471a5669-d584-4dd5-af9e-152f8f37c0fb.pdf
View document text
24th August 2026
Corporate Relationship Department The Manager - Listing
M/s. BSE Limited M/s. National Stock Exchange of India Ltd
Mumbai 400001 Bandra (E) Mumbai 400051
Scrip Code: 524816 Scrip Code: NATCOPHARM
Dear Sir/Madam,
Sub: Intimation of Schedule of Investors Meet
Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015 (“Listing Regulations”)
Pursuant to Regulation 30(6) read with Para A of Part A of Schedule III of the Listing Regulations, this
is to inform you that the officials of the company will be participating in the following investor meeting:
Date of Time Investor / Meeting Type of Nature of Location
meeting name meeting Meeting
Thursday, 9:00 AM to Investors meeting In-person Group Mumbai,
27th August 6:00 PM organised by Nuvama meeting Maharashtra
2026 Wealth Management
Thursday, 9:00 AM to Limited and ICICI Hong Kong
27th August 5:00 PM on Securities Limited
2026 to 27th August
Friday, 28th 2026 and
August 2026 9:00 AM to
1:00 PM 28th
August 2026
The latest investors’ presentation to be discussed has already been placed on the website of the
Company i.e., https://admin.natcopharma.co.in/wp-
content/uploads/2026/08/InvestorPresentation19082026.pdf
The schedule of the above-mentioned meeting is subject to change, and the change may occur due to
exigencies on the part of Investor / Company.
No Unpublished Price Sensitive Information (UPSI) pertaining to the Company is intended to be
discussed during the interactions.
Kindly take the same on record.
Thanking you,
Yours faithfully,
For NATCO Pharma Limited
Ch. Venkat Ramesh
Company Secretary &
Compliance Officer